Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Cancer Causes & Control
Erschienen in: Cancer Causes & Control 4/2011

01.04.2011 | Review article

Estrogens in the breast tissue: a systematic review

verfasst von: Lusine Yaghjyan, Graham A. Colditz

Erschienen in: Cancer Causes & Control | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

The role of estrogens in breast carcinogenesis has been investigated at the level of whole body (plasma) and cell (molecular, receptors, etc.). Growing attention focused on the breast tissue being an intracrine organ, with potentially important local estrogen production in the breast. However, very little is known about the local breast tissue estrogen levels. Understanding the role of the tissue estrogens in breast carcinogenesis might open new avenues in breast cancer prevention. This systematic review summarizes published studies that measured local estrogen levels in the breast and offers suggestions for strategies to fill gaps in our existing scientific knowledge.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Eliassen AH, Hankinson SE (2008) Endogenous hormone levels and risk of breast, endometrial and ovarian cancers: prospective studies. Adv Exp Med Biol 630:148–165PubMedCrossRef
2.
Giese RW (2003) Measurement of endogenous estrogens: analytical challenges and recent advances. J Chromatogr A 1000(1–2):401–412PubMedCrossRef
3.
Pattarozzi A, Gatti M, Barbieri F et al (2008) 17beta-estradiol promotes breast cancer cell proliferation-inducing stromal cell-derived factor-1-mediated epidermal growth factor receptor transactivation: reversal by gefitinib pretreatment. Mol Pharmacol 73(1):191–202PubMedCrossRef
4.
LaMarca HL, Rosen JM (2007) Estrogen regulation of mammary gland development and breast cancer: amphiregulin takes center stage. Breast Cancer Res 9(4):304PubMedCrossRef
5.
Russo J, Fernandez SV, Russo PA et al (2006) 17-Beta-estradiol induces transformation, tumorigenesis in human breast epithelial cells. FASEB J 20(10):1622–1634PubMedCrossRef
6.
Seeger H, Deuringer FU, Wallwiener D, Mueck AO (2004) Breast cancer risk during HRT: influence of estradiol metabolites on breast cancer and endothelial cell proliferation. Maturitas 49(3):235–240PubMedCrossRef
7.
Johansson CM, Anderson TJ, Bergstrom R, Lindgren A, Persson IR (1998) Epithelial proliferation in the normal human breast in relation to endogenous hormones and oral contraceptive use. Breast 7:162–167CrossRef
8.
Sutherland RL, Prall OW, Watts CK, Musgrove EA (1998) Estrogen progestin regulation of cell cycle progression. J Mammary Gland Biol Neoplasia 3(1):63–72PubMedCrossRef
9.
Foidart JM, Colin C, Denoo X et al (1998) Estradiol, progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril 69(5):963–969PubMedCrossRef
10.
Pike MC, Spicer DV, Dahmoush L, Press MF (1993) Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 15(1):17–35PubMed
11.
12.
Clemons M, Goss P (2001) Estrogen and the risk of breast cancer. N Engl J Med 344(4):276–285PubMedCrossRef
13.
Rosner B, Colditz GA (1996) Nurses’ health study: log-incidence mathematical model of breast cancer incidence. J Natl Cancer Inst 88(6):359–364PubMedCrossRef
14.
Paffenbarger RS Jr, Kampert JB, Chang HG (1980) Characteristics that predict risk of breast cancer before, after the menopause. Am J Epidemiol 112(2):258–268PubMed
15.
Zhu BT, Conney AH (1998) Functional role of estrogen metabolism in target cells: review, perspectives. Carcinogenesis 19(1):1–27PubMedCrossRef
16.
Westerlind KC, Gibson KJ, Evans GL, Turner RT (2000) The catechol estrogen, 4-hydroxyestrone, has tissue-specific estrogen actions. J Endocrinol 167(2):281–287PubMedCrossRef
17.
Telang NT, Suto A, Wong GY, Osborne MP, Bradlow HL (1992) Induction by estrogen metabolite 16 alpha-hydroxyestrone of genotoxic damage and aberrant proliferation in mouse mammary epithelial cells. J Natl Cancer Inst 84(8):634–638PubMedCrossRef
18.
McCormack VA, Dowsett M, Folkerd E et al (2009) Sex steroids, growth factors and mammographic density: a cross-sectional study of UK postmenopausal Caucasian and Afro-Caribbean women. Breast Cancer Res 11(3):R38PubMedCrossRef
19.
Levina VV, Nolen B, Su Y et al (2009) Biological significance of prolactin in gynecologic cancers. Cancer Res 69(12):5226–5233PubMedCrossRef
20.
Dabrosin C (2005) Positive correlation between estradiol and vascular endothelial growth factor but not fibroblast growth factor-2 in normal human breast tissue in vivo. Clin Cancer Res 11(22):8036–8041PubMedCrossRef
21.
Tamimi RM, Byrne C, Colditz GA, Hankinson SE (2007) Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 99(15):1178–1187PubMedCrossRef
22.
Zhu BT (1998) Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 19:1–27PubMedCrossRef
23.
Gruber CJ, Tschugguel W, Schneeberger C, Huber JC (2002) Production and actions of estrogens. N Engl J Med 346(5):340–352PubMedCrossRef
24.
Sasano H, Miki Y, Nagasaki S, Suzuki T (2009) In situ estrogen production, its regulation in human breast carcinoma: from endocrinology to intracrinology. Pathol Int 59(11):777–789PubMedCrossRef
25.
Sasano H, Nagasaki S, Miki Y, Suzuki T (2009) New developments in intracrinology of human breast cancer: estrogen sulfatase and sulfotransferase. Ann N Y Acad Sci 1155:76–79PubMedCrossRef
26.
Recchione CVE, Manzari A, Cavalerri A, Martinetti A, Secreto G (1995) Testosterone, dihydrotestosterone and oestradiol levels in postmenopausal breast cancer tissues. Steroid Biochem Molec Biol 52(6):541–546CrossRef
27.
Pasqualini JR, Chetrite G, Blacker C et al (1996) Concentrations of estrone, estradiol, estrone sulfate, evaluation of sulfatase, aromatase activities in pre-and postmenopausal breast cancer patients. J Clin Endocrinol Metab 81(4):1460–1464PubMedCrossRef
28.
Geisler J (2003) Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators. J Steroid Biochem Mol Biol 86:245–253PubMedCrossRef
29.
Labrie F, Luu-The V, Labrie C et al (2003) Endocrine, intracrine sources of androgens in women: inhibition of breast cancer, other roles of androgens, their precursor dehydroepiandrosterone. Endocr Rev 24(2):152–182PubMedCrossRef
30.
Guillemette C, Belanger A, Lepine J (2004) Metabolic inactivation of estrogens in breast tissue by UDP-glucuronosyltransferase enzymes: an overview. Breast Cancer Res 6(6):246–254PubMedCrossRef
31.
Shatalova EG, Walther SE, Favorova OO, Rebbeck TR, Blanchard RL (2005) Genetic polymorphisms in human SULT1A1 and UGT1A1 genes associate with breast tumor characteristics: a case-series study. Breast Cancer Res 7(6):R909–R921PubMedCrossRef
32.
Chetrite GS, Cortes-Prieto J, Philippe JC, Wright F, Pasqualini JR (2000) Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues. J Steroid Biochem Mol Biol 72(1–2):23–27PubMedCrossRef
33.
Riza E, dos Santos Silva I, De Stavola B et al (2001) Urinary estrogen metabolites, mammographic parenchymal patterns in postmenopausal women. Cancer Epidemiol Biomarkers Prev 10(6):627–634PubMed
34.
Greendale GA, Palla SL, Ursin G et al (2005) The association of endogenous sex steroids and sex steroid binding proteins with mammographic density: results from the Postmenopausal Estrogen/Progestin Interventions Mammographic Density Study. Am J Epidemiol 162(9):826–834PubMedCrossRef
35.
Tamimi RM, Hankinson SE, Colditz GA, Byrne C (2005) Endogenous sex hormone levels and mammographic density among postmenopausal women. Cancer Epidemiol Biomarkers Prev 14(11 Pt 1):2641–2647PubMedCrossRef
36.
Bremnes Y, Ursin G, Bjurstam N et al (2007) Endogenous sex hormones, prolactin and mammographic density in postmenopausal Norwegian women. Int J Cancer 121(11):2506–2511PubMedCrossRef
37.
Johansson H, Gandini S, Bonanni B et al (2008) Relationships between circulating hormone levels, mammographic percent density, breast cancer risk factors in postmenopausal women. Breast Cancer Res Treat 108(1):57–67PubMedCrossRef
38.
Thomas H, Reeves G, Key T (1997) Endogenous estrogen and postmenopausal breast cancer: a quantitative review. Cancer Causes Control 8(6):922–928PubMedCrossRef
39.
Sheila Dawling DLH, Nady R, Fritz FP (2004) In vitro model of mammary estrogen metabolism: structural and kinetic differences between catechol estrogens 2- and 4-hydroxyestradiol. Chem Res Toxicol 17:1258–1264PubMedCrossRef
40.
Leane Lehmann JW (2008) Gene expression of 17b-estradiol-metabolizing isozymes: comparison of normal human mammary gland to normal human liver and to cultured human breast adenocarcinoma cells. Adv Exp Med Biol Hormonal Carcinogenesis V 617:617–624CrossRef
41.
Rosselli MDR (2006) Estrogen metabolism and reproduction—is there a relationship? J für Fertilität und Reproduktion 16:19–23
42.
Liehr JG (2001) Genotoxicity of the steroidal oestrogens oestrone and oestradiol: possible mechanism of uterine and mammary cancer development. Human Reproduction Update 2001 7(3):273–281
43.
Westerlind KCGK, Evans GL, Turner RT (2000) The catechol estrogen, 4-hydroxyestrone, has tissue-specific estrogen actions. J Endocrinol 167:281–287PubMedCrossRef
44.
Telang NTSA, Wong GY, Osborne MP, Bradlow HL (1992) Induction by estrogen metabolite 16α-hydroxestrone of genotoxic damage and aberrant proliferation in mouse mammary epithelial cells. J Natl Cancer Inst 84:634–638PubMedCrossRef
45.
Osborne MPBH, Wong GYC, Telang NT (1993) Upregulation of estradiol C16alpha-hydroxylation in human breast tissue: a potential biomarker of breast cancer risk. J Natl Cancer Inst 85:1917–1920PubMedCrossRef
46.
Santen RJ, Santner SJ, Pauley RJ et al (1997) Estrogen production via the aromatase enzyme in breast carcinoma: which cell type is responsible? J Steroid Biochem Mol Biol 61(3–6):267–271PubMedCrossRef
47.
Shekhar M, Pauley R, Heppner G (2003) Host microenvironment in breast cancer development: Extracellular matrix-stromal cell contribution to neoplastic phenotype of epithelial cells in the breast. Breast Cancer Res 5(3):130–135PubMedCrossRef
48.
Reed MJ, Purohit A (1997) Breast cancer and the role of cytokines in regulating estrogen synthesis: an emerging hypothesis. Endocr Rev 18(5):701–715PubMedCrossRef
49.
Roy D, Cai Q, Felty Q, Narayan S (2007) Estrogen-induced generation of reactive oxygen, nitrogen species, gene damage, estrogen-dependent cancers. J Toxicol Environ Health B Crit Rev 10(4):235–257PubMed
50.
Mueck AO, Seeger H (2007) Breast cancer: are oestrogen metabolites carcinogenic? Maturitas 57(1):42–46PubMedCrossRef
51.
Li T, Sun L, Miller N et al (2005) The association of measured breast tissue characteristics with mammographic density, other risk factors for breast cancer. Cancer Epidemiol Biomarkers Prev 14(2):343–349PubMedCrossRef
52.
Ernster VL, Wrensch MR, Petrakis NL et al (1987) Benign, malignant breast disease: initial study results of serum, breast fluid analyses of endogenous estrogens. J Natl Cancer Inst 79(5):949–960PubMed
53.
Recchione C, Venturelli E, Manzari A et al (1995) Testosterone, dihydrotestosterone, oestradiol levels in postmenopausal breast cancer tissues. J Steroid Biochem Mol Biol 52(6):541–546PubMedCrossRef
54.
Vermeulen A, Deslypere JP, Paridaens R et al (1986) Aromatase, 17 beta-hydroxysteroid dehydrogenase, intratissular sex hormone concentrations in cancerous, normal glandular breast tissue in postmenopausal women. Eur J Cancer Clin Oncol 22(4):515–525PubMedCrossRef
55.
van Landeghem AA, Poortman J, Nabuurs M, Thijssen JH (1985) Endogenous concentration, subcellular distribution of estrogens in normal, malignant human breast tissue. Cancer Res 45(6):2900–2906PubMed
56.
Beattie CW, Briele HA, Hart G, Das Gupta TK (1983) Estradiol and progesterone in human breast cancer cytosols and their relationship to receptor incidence. Cancer Invest 1(3):199–206PubMedCrossRef
57.
Garvin S, Dabrosin C (2008) In vivo measurement of tumor estradiol and vascular endothelial growth factor in breast cancer patients. BMC Cancer 8:73PubMedCrossRef
58.
O’Brien SN, Anandjiwala J, Price TM (1997) Differences in the estrogen content of breast adipose tissue in women by menopausal status, hormone use. Obstet Gynecol 90(2):244–248PubMedCrossRef
59.
Blankenstein MA, Maitimu-Smeele I, Donker GH et al (1992) On the significance of in situ production of oestrogens in human breast cancer tissue. J Steroid Biochem Mol Biol 41(3–8):891–896PubMedCrossRef
60.
Thijssen JH, Blankenstein MA, Donker GH, Daroszewski J (1991) Endogenous steroid hormones and local aromatase activity in the breast. J Steroid Biochem Mol Biol 39(5B):799–804PubMedCrossRef
61.
Lonning PE, Helle H, Duong NK et al (2009) Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status. J Steroid Biochem Mol Biol 117(1–3):31–41PubMedCrossRef
62.
Reed MJ, Aherne GW, Ghilchik MW, Patel S, Chakraborty J (1991) Concentrations of oestrone and 4-hydroxyandrostenedione in malignant and normal breast tissues. Int J Cancer 49(4):562–565PubMedCrossRef
63.
Bonney RC, Reed MJ, Davidson K, Beranek PA, James VH (1983) The relationship between 17 beta-hydroxysteroid dehydrogenase activity, oestrogen concentrations in human breast tumours, in normal breast tissue. Clin Endocrinol (Oxf) 19(6):727–739CrossRef
64.
Hankinson SE, Willett WC, Manson JE et al (1995) Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J Natl Cancer Inst 87(17):1297–1302PubMedCrossRef
65.
Hankinson SE, Eliassen AH (2007) Endogenous estrogen, testosterone, progesterone levels in relation to breast cancer risk. J Steroid Biochem Mol Biol 106(1–5):24–30PubMedCrossRef
66.
Missmer SA, Spiegelman D, Bertone-Johnson ER et al (2006) Reproducibility of plasma steroid hormones, prolactin, insulin-like growth factor levels among premenopausal women over a 2-to 3-year period. Cancer Epidemiol Biomarkers Prev 15(5):972–978PubMedCrossRef
67.
Michaud DS, Manson JE, Spiegelman D et al (1999) Reproducibility of plasma, urinary sex hormone levels in premenopausal women over a one-year period. Cancer Epidemiol Biomarkers Prev 8(12):1059–1064PubMed
68.
Thomas HV, Key TJ, Allen DS et al (1997) A prospective study of endogenous serum hormone concentrations and breast cancer risk in premenopausal women on the island of Guernsey. Br J Cancer 75(7):1075–1079PubMedCrossRef
69.
Boyapati SM, Shu XO, Gao YT et al (2004) Correlation of blood sex steroid hormones with body size, body fat distribution, other known risk factors for breast cancer in post-menopausal Chinese women. Cancer Causes Control 15(3):305–311PubMedCrossRef
70.
Potischman N, Swanson CA, Siiteri P, Hoover RN (1996) Reversal of relation between body mass and endogenous estrogen concentrations with menopausal status. J Natl Cancer Inst 88(11):756–758PubMedCrossRef
71.
Kopelman PG, Pilkington TR, White N, Jeffcoate SL (1980) Abnormal sex steroid secretion, binding in massively obese women. Clin Endocrinol (Oxf) 12(4):363–369CrossRef
72.
Zumoff B (1982) Relationship of obesity to blood estrogens. Cancer Res 42(8 Suppl):3289s–3294sPubMed
73.
De Pergola G, Giorgino F, Cospite MR et al (1993) Relation between sex hormones, serum lipoprotein, lipoprotein(a) concentrations in premenopausal obese women. Arterioscler Thromb 13(5):675–679PubMed
74.
Grenman S, Ronnemaa T, Irjala K, Kaihola HL, Gronroos M (1986) Sex steroid, gonadotropin, cortisol, prolactin levels in healthy, massively obese women: correlation with abdominal fat cell size, effect of weight reduction. J Clin Endocrinol Metab 63(6):1257–1261PubMedCrossRef
75.
Van Beek AP, de Ruijter-Heijstek FC, Jansen H, Erkelens DW, de Bruin TW (2004) Sex steroids, plasma lipoprotein levels in healthy women: The importance of androgens in the estrogen-deficient state. Metabolism 53(2):187–192PubMedCrossRef
76.
Caron P, Audet-Walsh E, Lepine J, Belanger A, Guillemette C (2009) Profiling endogenous serum estrogen and estrogen-glucuronides by liquid chromatography-tandem mass spectrometry. Anal Chem 81(24):10143–10148PubMedCrossRef
77.
Blankenstein MA, van de Ven J, Maitimu-Smeele I et al (1999) Intratumoral levels of estrogens in breast cancer. J Steroid Biochem Mol Biol 69(1–6):293–297PubMedCrossRef
78.
Chatterton RT Jr, Geiger AS, Khan SA et al (2004) Variation in estradiol, estradiol precursors, estrogen-related products in nipple aspirate fluid from normal premenopausal women. Cancer Epidemiol Biomarkers Prev 13(6):928–935PubMed
79.
Dabrosin C (2005) Increased extracellular local levels of estradiol in normal breast in vivo during the luteal phase of the menstrual cycle. J Endocrinol 187(1):103–108PubMedCrossRef
80.
Yue W, Wang JP, Hamilton CJ, Demers LM, Santen RJ (1998) In situ aromatization enhances breast tumor estradiol levels and cellular proliferation. Cancer Res 58(5):927–932PubMed
81.
Xu X, Veenstra TD, Fox SD et al (2005) Measuring fifteen endogenous estrogens simultaneously in human urine by high-performance liquid chromatography-mass spectrometry. Anal Chem 77(20):6646–6654PubMedCrossRef
82.
Falk RT, Xu X, Keefer L, Veenstra TD, Ziegler RG (2008) A liquid chromatography-mass spectrometry method for the simultaneous measurement of 15 urinary estrogens, estrogen metabolites: assay reproducibility, interindividual variability. Cancer Epidemiol Biomarkers Prev 17(12):3411–3418PubMedCrossRef
83.
Carlstrom K (1996) Low endogenous estrogen levels—analytical problems and tissue sensitivity. Acta Obstet Gynecol Scand Suppl 163:11–15PubMed
84.
Nelson RE, Grebe SK, DJ OK, Singh RJ (2004) Liquid chromatography-tandem mass spectrometry assay for simultaneous measurement of estradiol, estrone in human plasma. Clin Chem 50(2):373–384PubMedCrossRef
85.
Bay K, Andersson AM, Skakkebaek NE (2004) Estradiol levels in prepubertal boys, girls–analytical challenges. Int J Androl 27(5):266–273PubMedCrossRef
86.
Blonder J, Johann DJ, Veenstra TD et al (2008) Quantitation of steroid hormones in thin fresh frozen tissue sections. Anal Chem 80(22):8845–8852PubMedCrossRef
87.
Xu X, Roman JM, Issaq HJ et al (2007) Quantitative measurement of endogenous estrogens and estrogen metabolites in human serum by liquid chromatography-tandem mass spectrometry. Anal Chem 79(20):7813–7821PubMedCrossRef
88.
Xu X, Keefer LK, Ziegler RG, Veenstra TD (2007) A liquid chromatography-mass spectrometry method for the quantitative analysis of urinary endogenous estrogen metabolites. Nat Protoc 2(6):1350–1355PubMedCrossRef
89.
Xu X, Othman Eel D, Issaq HJ et al (2008) Multiplexed quantitation of endogenous estrogens, estrogen metabolites in human peritoneal fluid. Electrophoresis 29(12):2706–2713PubMedCrossRef
90.
Mady EA, Ramadan EE, Ossman AA (2000) Sex steroid hormones in serum and tissue of benign and malignant breast tumor patients. Dis Markers 16(3–4):151–157PubMed
Metadaten
Titel
Estrogens in the breast tissue: a systematic review
verfasst von
Lusine Yaghjyan
Graham A. Colditz
Publikationsdatum
01.04.2011
Verlag
Springer Netherlands
Erschienen in
Cancer Causes & Control / Ausgabe 4/2011
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-011-9729-4

Weitere Artikel der Ausgabe 4/2011

Cancer Causes & Control 4/2011 Zur Ausgabe

Original paper

Associations of body size and reproductive factors with circulating levels of sex hormones and prolactin in premenopausal Japanese women

Original paper

Birth characteristics and female sex hormone concentrations during adolescence: results from the Dietary Intervention Study in Children

Original paper

Cigarette smoking shortens the survival of patients with low-risk myelodysplastic syndromes

Original paper

Cancer survival among Latinos and the Hispanic Paradox

Original paper

Healthy eating index and ovarian cancer risk

Original paper

Variation in folate pathway genes and distal colorectal adenoma risk: a sigmoidoscopy-based case–control study

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise